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Chronic Phospholamban±Sarcoplasmic Reticulum
Calcium ATPase Interaction Is the Critical Calcium
Cycling Defect in Dilated Cardiomyopathy
decrease in contractile elements, myofilament disarray,
and interstitial fibrosis. Recently, the activation of signal
transduction pathways that trigger the onset of pro-
grammed cell death has been implicated in promoting
this pathological transition, as well as a gp130-depen-
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In this regard, the sarcoplasmic reticulum (SR) playsCanada
an integral role in the coordination of the movement of
cytosolic Ca21 during each cycle of cardiac contraction
and relaxation. Ca21 stored in the SR is released intoSummary
the cytosol to activate the contraction of cardiac muscle
and subsequently reaccumulated to achieve relaxation.Dilated cardiomyopathy and end-stage heart failure
Activity of the cardiac SR Ca21 ATPase (SERCA2a) isresult in multiple defects in cardiac excitation±con-
the rate-determining factor of Ca21 reuptake into thetraction coupling. Via complementation of a geneti-
SR, and SERCA2a activity is itself regulated by phospho-cally based mouse model of dilated cardiomyopathy,
lamban (PLB), a 52±amino acid muscle-specific SR phos-we now provide evidence that progressive chamber
phoprotein (Koss and Kranias, 1996; Simmerman anddilation and heart failure are dependent on a Ca21 cy-
Jones, 1998; Tada and Toyofuku, 1998). PLB inhibitscling defect in the cardiac sarcoplasmic reticulum.
SERCA2a activity in its unphosphorylated form, whereasThe ablation of a muscle-specific sarcoplasmic reticu-
the phosphorylated form of PLB dissociates from SER-lum Ca21 ATPase (SERCA2a) inhibitor, phospholamban,
CA2a. Under physiological conditions, phosphorylationrescued the spectrum of phenotypes that resemble
at serine-16 by PKA is the predominant event that leadshuman heart failure. Inhibition of phospholamban±
to proportional increases in the rate of Ca21 uptake intoSERCA2a interaction via in vivo expression of a phos-
SR and accelerates ventricular relaxation (Tada et al.,pholamban point mutant dominantly activated the
1982; Luo et al., 1998).contractility of ventricular muscle cells. Thus, interfer-
A decrease in Ca21 uptake is a central feature of hu-
ing with phospholamban±SERCA2a interaction may
man and animal heart failure (Sordahl et al., 1973;
provide a novel therapeutic approach for preventing
Whitmer et al., 1988), and an increase in the relative
the progression of dilated cardiomyopathy. ratio of PLB to SERCA2a is an important determinant
of SR dysfunction in heart failure (Meyer et al., 1995;Introduction
Hasenfuss, 1998). To directly assess the role of Ca21
cycling defects in the transition to heart failure, the
Heart failure, the leading cause of combined morbidity
current study employed a genetic complementation
and mortality in the United States and other developed strategy in a well-characterized mouse model of dilated
nations, is a complex disease in which genetic pathways cardiomyopathy, which harbors a deficiency in a cytoskel-
that confer susceptibility are interwoven with the envi- etal protein, the muscle-specific LIM protein (MLP) (Arber
ronmental stimulus of biomechanical stress (Hunter and et al., 1997). The present report demonstrates that the
Chien, 1999). In response to this biomechanical stress, progressive defects in EC coupling in dilated cardiomy-
a series of parallel and converging signaling pathways opathy are related to the enhanced inhibition of SER-
are activated that lead to the adaptive response of com- CA2a by PLB, and it shows that inhibition of either PLB
pensatory hypertrophy (Chien et al., 1999). Subsequently, expression or PLB±SERCA2a interaction can prevent
there can be a transition to chamber dilation and pump heart failure.
failure that is associated with a loss of viable myocytes, a
Results
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and characteristics of both the PLBKO and MLPKO mice
have been previously described in detail elsewhere (Luo
et al., 1994; Arber et al., 1997). As described in Experi-
mental Procedures, the F4 generation of these mice was
used for the current studies to eliminate any potential
background effects from either the PLBKO or MLPKO
line on the observed cardiac phenotype of the double
MLP/PLB knockout (DKO) line. MLPKO mice displayed
a marked increase in heart:body weight ratio (6.34 6
0.22 mg/g, n 5 8) versus age- and gender-matched wild-
type mice (4.60 6 0.21 mg/g, n 5 7; p , 0.001). The
heart:body weight ratio in DKO mice (5.13 6 0.19 mg/g,
n 5 9) was significantly smaller than that of MLPKO
mice (p , 0.01). Histological analyses of hearts from
MLPKO and DKO littermates showed that ablation of
PLB in the background of MLP2/2 mice rescued the wide
spectrum of morphological and ultrastructural defects
originally observed in the MLP-deficient hearts, includ-
ing chamber dilation, myofibrillar disarray, and massive
fibrosis (Arber et al., 1997; Figure 1). These data suggest
that ablation of PLB prevents not only the increase in
total heart mass, but also the disorganization of cardio-
myocyte cytoarchitecture and fibrosis in MLPKO cardio-
myopathic mice. Interestingly, this latter effect on inhibi-
tion of fibrosis was not observed in parallel studies
(Rockman et al., 1998) employing transgenic mice that
express an inhibitory peptide for the b-adrenergic recep-
tor kinase (Koch et al. 1995). While the basis for this
discrepancy is unclear, it may reflect the mosaic expres-
sion of the transgene versus the uniform deletion of PLB
in the present study.
PLB Ablation Rescues In Vivo Cardiac Function
in MLPKO Mice
To determine whether the marked decreases observed
in in vivo global cardiac function are rescued in DKO
mice, echocardiography was performed with age-
matched littermates. As noted in Figure 2A, prevention
of ventricular dilation was confirmed in DKO mice.
MLPKO mice had enlarged cardiac chambers, as re- Figure 1. Rescue of Ultrastructural Defects and Fibrosis in DKO
Heartsvealed by increased left ventricular end-diastolic dimen-
Histological analyses of transverse sections with hematoxylin-eosinsions (LVEDD) and end-systolic dimensions (LVESD),
(A and B) and trichrome (C and D) stain from MLPKO and DKOwhereas DKO mice had LVEDD in the normal range. The
hearts. Marked chamber dilation (A) and massive fibrosis (red color,percent fractional shortening (%FS) and mean velocity
[C]) in MLPKO hearts were rescued in DKO hearts (B and D). Electron
of circumferential fiber shortening (mean Vcf), indicators microscopic analysis documented that myofibrillar disarray, pro-
of systolic cardiac function, were improved in age- nounced increases in nonmyofibrillar space (E), and massive fibrosis
matched DKO littermates (Table 1). When compared to (G) in MLPKO hearts were rescued in DKO hearts (F and H). Bars,
1 mm (A and B), 0.5 mm (C and D), 1.0 mm (E and F), and 2.5 mmnonlittermate wild-type mice as controls, most of the
(G and H).echocardiographic data in DKO mice were similar to
those in wild-type mice, although heart rate was slightly
decreased in DKO mice (Table 1). Despite the reduction
heterozygous for PLB deficiency displayed an interme-of chamber dilation, there appeared to be some hyper-
diate level of functional rescue versus the MLPKO andtrophy in DKO hearts, as there was a slight increase
DKO mice (Table 1), suggesting that partial ablation ofin heart:body weight ratio. The ratio of LVEDD to LV
PLB can lead to significant functional improvement ofposterior wall thickness was markedly decreased in
the heart failure phenotype in MLPKO mice.DKO mice, indicating that the wall stress of DKO mice
was markedly reduced, when compared to MLPKO or
wild-type mice. These results indicate that global car- PLB Deficiency in the Setting of the Cardiomyopathic
MLP Mutation Results in a Maximal Effect ondiac function of DKO mice was preserved in the range
comparable to the parameters of control hearts. Further- Cardiac Contractility in the DKO Hearts
Previous studies have demonstrated a marked bluntingmore, all of the various parameters of improved cardiac
function remained in an older subset of DKO mice at 6 of b-adrenergic responsiveness (Arber et al., 1997) and
decreased adenylyl cyclase activity in MLPKO micemonths of age, indicating the longevity of the rescue
effect (Table 1). It should be noted that mice which are (Rockman et al., 1998). Ablation of PLB by homologous
PLB Ablation Prevents Progression of Heart Failure
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Figure 2. Rescue of In Vivo Cardiac Dysfunc-
tion in DKO Mice
(A) Transthoracic M-mode echocardiographic
tracings in a MLPKO mouse (top) and a DKO
mouse (bottom). Left ventricular (LV) dimen-
sions are indicated by the double-sided
arrows. EDD, end diastolic dimension; ESD,
end systolic dimension. MLPKO mouse has
chamber dilatation with reduced wall motion,
indicating depressed cardiac function and in-
creased wall stress, whereas chamber size
and cardiac function are normal in the DKO
mouse.
(B±I) Maximal in vivo cardiac contractility and
rescue of diastolic dysfunction in DKO mice.
Cardiac catheterization was performed at
basal condition in intact, anesthetized mice
of wild type (WT), n 5 7, MLPKO, n 5 8, DKO,
n 5 9, and PLBKO, n 5 5. (B) Maximal first
derivative of LV pressure, LV dP/dtmax, (C)
minimal first derivative of LV pressure, LV dP/
dtmin, (D) LV end diastolic pressure, (E) Tau.
(F±I) b-adrenergic responsiveness by pro-
gressive infusion of dobutamine. Wild-type
(open squares), n 5 7, MLPKO (filled circles),
n 5 8, and DKO (open circles), n 5 9, mice.
(F) LV dP/dtmax. (G) LV dP/dtmin, (H) LV end
diastolic pressure, (I) heart rate. Data were
expressed as mean 6 SEM. MLPKO versus
DKO or wild type, or PLBKO; 1, p , 0.05; *,
p , 0.01; **, p , 0.001, WT versus DKO or
PLBKO; #, p , 0.01.
recombination in mice can augment cardiac contractile intact anesthetized mice. Several independent hemody-
namic parameters document the rescue of the severeperformance to a level comparable to that with maximal
b-adrenergic stimulation of the normal heart (Luo et al., cardiac dysfunction with circulatory congestion to nor-
mal levels in the DKO mice. LV contractility (assessed1994). To determine whether ablation of PLB can reverse
the hemodynamic defects and marked b-adrenergic re- by LV dP/dtmax) and relaxation (assessed by LVdP/
dtmin) at baseline in the DKO mice was significantlyceptor desensitization associated with dilated cardio-
myopathy, we performed cardiac catheterization in larger than that of wild-type mice and was comparable
Table 1. Rescue of Cardiac Chamber Dilation and Dysfunction in DKO Mice
Wild Type MLPKO MLPKO/PLBhet DKO DKO
(2 Months, n 5 6) (2 months, n 5 12) (2 months, n 5 10) (2 months, n 5 12) (6 months, n 5 8)
LVEDD (mm) 3.39 6 0.11 4.87 6 0.14²²² 4.10 6 0.15²²*** 3.75 6 0.12*** 3.81 6 0.12
LVESD (mm) 2.30 6 0.07 3.94 6 0.18²²² 3.06 6 0.22²***# 2.60 6 0.10*** 2.46 6 0.13
FS (%) 32.0 6 0.9 19.4 6 1.7²² 26.2 6 3.2* 30.6 6 1.8** 35.5 6 3.1
SEPth (mm) 0.70 6 0.06 0.68 6 0.05 0.86 6 0.05 0.83 6 0.05 0.89 6 0.06
PWth (mm) 0.67 6 0.05 0.67 6 0.05 0.86 6 0.05* 0.81 6 0.04 0.83 6 0.05
LVEDD/PWth (mm/mm) 5.23 6 0.45 7.47 6 0.30²² 5.00 6 0.47** 4.74 6 0.30*** 4.77 6 0.42
Mean Vcfc (circ/s) 2.62 6 0.15 1.41 6 0.17²² 1.96 6 0.27* 2.37 6 0.13*** 2.94 6 0.30
Heart rate (beats/min) 461 6 22 351 6 15²²² 350 6 15²²² 396 6 13²* 466 6 24³
Age (days) 62 6 0 65 6 3 66 6 5 67 6 2 182 6 1§
Body weight (g) 23.3 6 2.8 26.7 6 1.3 26.8 6 0.9 25.0 6 1.3 37.8 6 3.4§
LVEDD, left ventricular end-diastolic left ventricular dimension; LVESD, left ventricular end-systolic left ventricular dimension; %FS, percent
fractional shortening calculated as %FS5[(EDD-ESD)/EDD]3100; SEPth, intraventricular septal wall thickness; PWth, left ventricular posterior
wall thickness; mean Vcfc, heart rate±corrected mean velocity of circumferential fiber shortening. Data were expressed as mean 6 SEM.
², p , 0.05; ²², p , 0.01; ²²², p , 0.001; wild type versus MLPKO or MLPKO/PLBhet or DKO (2 months).
*, p , 0.05; **, p , 0.01; ***, p , 0.001; MLPKO versus MLPKO/PLBhet or DKO (2 months).
#, p , 0.05; MLPKO/PLBhet versus DKO (2 months).
³, p , 0.01; §, p , 0.001; DKO (2 months) versus DKO (6 months).
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Table 2. Long-Term Rescue of Cardiac Dysfunction in DKO Mice
Heart Rate LV Systolic Pressure LV dP/dt max LV dP/dt min LVEDP
(Beats/min) (mmHg) (mmHg/s) (mmHg/s) (mmHg) Tau (s) Age (Days)
MLPKO (n 5 4) 253 6 14 90.4 6 15.1 4694 6 540** 21704 6 237** 20.1 6 8.8 50.9 6 7.1* 259 6 43
DKO (n 5 5) 320 6 36 123.7 6 16.4 13190 6 686 27081 6 672 2.5 6 3.3 17.6 6 4.7 250 6 40
MLPKO versus DKO; *, p , 0.01; **, p , 0.001.
to PLBKO mice (Figures 2B and 2C). Ablation of PLB amplitude when compared to wild-type mice (Figures
3A±3C). SR Ca21 content was significantly decreased inreversed the markedly elevated LV end diastolic pres-
sure observed in the MLPKO cardiomyopathic mice (Fig- MLPKO mice and increased in DKO mice as compared
to wild-type mice (Figure 3D). Quantitative immunoblot-ure 2D). Tau, an indicator of LV relaxation and diastolic
function, was also normalized in the DKO mice (Figure ting revealed that MLP deficiency did not cause any
significant alterations in protein levels of SERCA2a, PLB,2E), which is consistent with a marked reduction in wall
stress. These data suggest that ablation of PLB can calsequestrin (Figure 3E), ryanodine receptors, and
L-type Ca21 channels (data not shown), suggesting thatrescue both the systolic and diastolic dysfunction in the
cardiomyopathic MLPKO mice. The suprarescue effects the defects of Ca21 cycling in MLPKO mice result from
functional impairment of EC coupling, as opposed toon contractility and relaxation were maintained over the
long term, as assessed by hemodynamic analysis in a simply reflecting decreases in the protein levels of Ca21
cycling.subset of DKO (n 5 5) and MLPKO (n 5 4) mice at 8
months of age (Table 2).
The blunted responses of LV dP/dtmax and LVdP/ Rescue of Embryonic Gene Markers of the Heart
Failure Phenotype in DKO Micedtmin to b-adrenergic stimulation were observed in
MLPKO mice (Figures 2F and 2G), indicating the pres- One of the characteristic features of heart failure is the
reactivation of an embryonic gene program, which mayence of severe b-adrenergic desensitization in MLPKO
mice. There was no stimulation of cardiac contractility contribute to a compensatory response to an increased
hemodynamic load (Chien et al., 1993). Ventricles of(LV dP/dtmax) and relaxation (LV dP/dtmin) to dobuta-
mine in DKO mice (Figures 2F and 2G). These parameters MLPKO mice displayed a 26-fold increase in ANF, a 13-
fold increase in a-skeletal actin, and an 8-fold enhance-were already stimulated to their maximal levels under
basal conditions in the DKO hearts. In fact, after maxi- ment of b-MHC mRNAs (Figure 3F). Strikingly, DKO mice
exhibited only a 1.9-fold increase in ANF, and no signifi-mum stimulation of wild-type hearts by dobutamine, LV
dP/dtmax and LV dP/dtmin were indistinguishable from cant increase in a-skeletal actin or b-MHC mRNAs.
Thus, ablation of PLB largely suppresses induction ofthese parameters in the DKO mice in the absence of any
catecholamine stimulation. In summary, these results the embryonic gene program in MLPKO mice.
suggest that the interaction of PLB and SERCA2a sup-
presses cardiac contractility in both normal and myo- Inhibition of the Interaction between PLB
and SERCA2a Dominantly Activatespathic hearts, and that inhibiting this interaction may
exert a dominant effect on maximizing cardiac perfor- Cardiac Contractility
To define the molecular mechanism of the rescue effect,mance in the absence of any catecholamine stimulation.
Chronotropic responsiveness to dobutamine was pre- it was necessary to assess whether the chronic interac-
tion of PLB and SERCA2a is indeed limiting for cardiacserved in both DKO mice and MLPKO mice (Figure 2I),
thereby documenting the specificity of the b-adrenergic contractility in both normal and myopathic hearts. Inter-
estingly, the suprarescue of basal cardiac function inresponse to ventricular myocytes versus pacemaker cell
types. the DKO mice to levels comparable to those in wild-
type mice following maximal catecholamine stimulation
suggests that inhibition of this interaction may exert aRescue of Physiological Calcium Signaling Defects
in DKO Myocytes dominant effect to maximize cardiac performance in
the absence of any catecholamine stimulation. PreviousTo gain further insight into the mechanisms responsible
for the rescue of in vivo cardiac function in DKO mice, studies by MacLennan and coworkers have identified
the PLB residues that are required to maintain its inhibi-we assessed several independent parameters of Ca21
signaling. Initial experiments explored whether altered tory effects on SERCA2a in vitro (Toyofuku et al., 1994;
Kimura et al., 1997, 1998). To directly test this conceptCa21 homeostasis in DKO mice leads to the hemody-
namic changes, intracellular Ca21 transients, and the ex- in vivo, we engineered a point mutation in PLB (V49A)
that can disrupt the inhibitory effects of PLB on SER-pression of proteins related to Ca21 cycling in the SR.
MLPKO myocytes exhibited an attenuated amplitude CA2a. Utilizing recombinant adenoviruses and a new
protocol for high efficiency, in vivo murine cardiac geneof Ca21 transients in the presence of normal levels of
diastolic Ca21 concentration (Figures 3A±3C). The rate transfer (Christensen et al., 1999), we documented that
myocytes which overexpress the V49A point mutationof decay was slightly accelerated in MLPKO mice, sug-
gesting that a compensatory mechanism is operative in PLB display increased contractility, while myocytes
which overexpress the wild-type PLB exhibit decreasedduring Ca21 uptake in MLPKO mice. Ablation of PLB in
MLPKO mice resulted in a shortened duration of the contractility when compared to noninfected myocytes
(Figure 4, Table 3). Thus, the feasibility and utility ofCa21 transient and faster decay, but no change in its
PLB Ablation Prevents Progression of Heart Failure
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Figure 3. Rescue of Physiological Calcium
Signaling Defects and Embryonic Gene Mark-
ers of the Heart Failure Phenotype in DKO
Mice
(A) Representative intracellular Ca21 transient
in WT, MLPKO, and DKO myocytes. MLPKO
myocytes exhibited an attenuated amplitude
of Ca21 transients with normal levels of dia-
stolic Ca21 concentration. DKO myocyte dis-
plays the Ca21 transient with a shortened dura-
tion, faster decay, and preserved amplitude.
(B) The amplitude of Ca21 transient was sig-
nificantly attenuated in MLPKO myocytes
and was restored in DKO myocytes.
(C) Intracellular diastolic Ca21 concentration
was not different among three groups.
(D) SR Ca21 content was significantly de-
creased in MLPKO mice and increased in
DKO mice when compared to wild-type mice.
MLPKO versus wild type or DKO; *, p , 0.05,
wild type versus DKO; #, p , 0.05.
(E) Quantitative immunoblotting analysis of
SR proteins. MLP deficiency did not cause
any significant alterations in protein levels of
SERCA2, PLB, and calsequestrin (CSQ). Sig-
nals were normalized to those of a wild type
standard, which were processed in parallel
and were set at 1.00. Each assayed in trip-
licate.
(F) Dot blot analyses in wild type (n 5 4),
MLPKO (n 5 4), and DKO (n 5 4). Oligonucleo-
tide probes: GAPDH, glyceraldehyde 3-phos-
phate dehydrogenase; ANF, atrial natriuretic
factor; a-skeletal actin; a-MHC, a-myosin
heavy chain; b-MHC, b-myosin heavy chain;
and a-cardiac actin. The expression of em-
bryonic genes was largely suppressed at
mRNA level in DKO mice.
interfering with the interaction between the SERCA2a in cardiac cytoskeletal proteins can serve as initiators
of both acquired and hereditary forms of dilated cardio-and PLB is clearly documented. In addition, PLB±
SERCA2 interaction appears to be the rate-limiting step myopathy (Chen and Chien, 1999). Defects in dystrophin
and the closely related dystroglycan complex (delta-for establishing the set point of basal cardiac contrac-
tility and relaxation in vivo, and the disruption of this sarcoglycan) have been documented as disease genes
in both clinical and experimental studies (Coral-Vazquezinteraction can thereby short circuit the b-adrenergic
pathway. et al., 1999). Recently, mice that harbor an ablation of the
muscle-specific LIM domain cytoskeletal protein (MLP)
have been shown to display many of the phenotypicDiscussion
features of human dilated cardiomyopathy at the molec-
ular, cellular, and physiological levels (Arber et al., 1997).Genetic Complementation to Identify Modifiers
Mutations in the cytoskeletal domains of cardiac a-actinof Heart Failure
have also been implicated in familial forms of humanDilated cardiomyopathy is a major form of human heart
dilated cardiomyopathy (Olson et al., 1998). Interest-failure, often initiated by environmental stimuli on a
ingly, acquired forms of dilated cardiomyopathy thatbackground of genetic susceptibility. In this regard, a
growing body of evidence has suggested that defects occur following the onset of enteroviral myocarditis have
Figure 4. Inhibition of the Interaction be-
tween PLB and SERCA2a Dominantly Acti-
vates Cardiac Contractility
Representative data of myocyte contraction.
Myocytes that overexpress the V49A point
mutation in PLB display increased contractil-
ity, while myocytes that overexpress the wild-
type PLB exhibit decreased contractility
when compared to noninfected myocytes.
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Table 3. Inhibition of the Interaction between PLB and SERCA2a Activates Cardiac Contractility
Control (n 5 7) Wild-Type PLB (n 5 3) V49A Mutant PLB (n 5 4)
Shortening (%) 7.20 6 0.60 3.50 6 0.24* 11.45 6 0.88**
2dL/dt (mm) 88.4 6 10.3 48.4 6 5.9* 150.3 6 9.6**²
1dL/dt (mm) 56.6 6 10.3 28.1 6 6.4 116.5 6 13.5**²
Cell length (mm) 104.5 6 3.1 109.2 6 3.9 108.7 6 3.3
n, number of animals (more than four cells were evaluated from each group) control versus wild-type or V49A mutant PLB; *, p , 0.01; **,
p , 0.001 wild-type PLB versus V49A mutant PLB; ², p , 0.001.
also been shown to converge on cytoskeletal pathways be based upon a known inhibitor of SERCA2a, PLB,
we attempted to genetically complement the onset of(Badorff et. al. 1999). The mechanisms that link cyto-
skeletal defects with the onset of chamber dilation and dilated cardiomyopathy and progression to overt heart
failure in the MLP-deficient mice by generating strainsthe associated decreases in cardiac contractility and
relaxation are unclear. The nature of the downstream that harbor a double mutation in both of these muscle-
specific genes, MLP and PLB. Remarkably, the doublemolecular pathways that account for defects in excita-
tion±contraction coupling in failing cardiac myocytes is knockout mice display a rescue of the entire spectrum
of the MLP-deficient heart failure phenotype at the struc-unknown. Presumably, since calcium cycling is critical
for both cardiac relaxation and contractility, defects in tural, functional, and molecular level. These studies have
been independently supported by our recent studies ofthe pathways that control calcium uptake and release
from the SR are prime candidates for driving the pro- MLP-deficient mice harboring a transgene which directs
cardiac-specific overexpression of SERCA2a, that alsogression of heart failure. However, direct evidence for
their causal relationship in the progression of heart fail- exhibit rescue of the cardiomyopathy phenotype (un-
published observations).ure and dilated cardiomyopathy has been lacking.
To critically address the question of the role of calcium Two independent lines of evidence indicate that these
findings in the MLP-deficient model may be generalizedcycling in the progression of in vivo heart failure in the
setting of dilated cardiomyopathy, the current study to other forms of cardiomyopathy. First, defects in the
peak calcium transients have now been documented inutilizes an in vivo genetic complementation strategy
employing the well-characterized MLP-deficient mouse isolated ventricular cells from end-stage failing hearts
in multiple experimental and clinical studies of cardio-model of dilated cardiomyopathy. As previously noted,
MLP is a muscle-specific cytoskeletal protein localized myopathy (Morgan, 1991; Pieske et al, 1995; Gomez et
al., 1997; Lindner et al., 1998). This defect in peak myo-at actin cytoskeleton-based structures along the Z lines
of cardiac and skeletal muscle, where it interacts with cyte calcium levels is accompanied by defects in con-
tractility, blunted b-adrenergic responsiveness, and de-a-actinin. MLP-deficient mice exhibit alterations of cardio-
myocyte shape, cytoskeletal abnormalities (Arber et al., creases in SR calcium uptake that are indistinguishable
from those found in the MLP model of dilated cardio-1997), adrenergic-receptor signaling (Arber et al., 1997;
Rockman et al., 1998), and electrophysiological changes myopathy. An increasing body of evidence has doc-
umented a close correlation between decreases in(unpublished observations) resembling those in acquired
and genetic forms of human dilated cardiomyopathy. In cardiac contractility and relaxation with alterations in
SERCA2a and PLB in the failing human heart (Meyer etthe current study, we document that there is a calcium
cycling defect in the MLP-deficient mice which relates al., 1995; Qi et al., 1997; Hasenfuss, 1998). Since im-
paired diastolic function often precedes systolic dys-to a decreased activity of the muscle-specific SERCA2a
to sequester intracellular calcium into the SR, resulting function in failing hearts, the loss of normal SR calcium
uptake may be an early key molecular event that initiatesin impairment in in vivo cardiac relaxation. The observed
decrease in SR calcium content results in a decrease a downward spiral to decompensated heart failure from
a variety of different stimuli. Recent studies have docu-in the quantal release of calcium through the calcium
release channel and a major decrease in the peak cal- mented a selective decrease in SR calcium ATPase:PLB
ratio at the protein level (Koss et al., 1997) in the failingcium transient, a characteristic feature of end-stage
heart failure. This defect in EC coupling is seen in many heart and have also found persistent decreases in the
phosphorylated state of PLB. Independent studies haveforms of heart failure and results in progressive cardiac
contractile dysfunction. There remains the formal possi- documented that PLB phosphorylation correlates with
the progression of heart failure in human and experimen-bility that physiological dissociation of L-type Ca21
channels and ryanodine receptors also plays a role in EC tal heart failure (Schmidt et al., 1999; Schwinger et al.,
1999; G. Christensen, personal communication). Thus,coupling defects in other forms of heart failure (Gomez et
al., 1997), since L-type Ca21 current density (Santana et there is now a clear consensus that defects in SR cal-
cium cycling are a conserved feature of many forms ofal, 1998) and protein levels of L-type Ca21 channels and
ryanodine receptors are not altered in MLPKO mice. cardiomyopathy in diverse mammalian species, includ-
ing human. Second, PLB ablation can rescue the defectsThe decreased SR calcium content was not due to a
decreased level of SERCA2a at the protein level, indicat- in contractility seen in another cardiomyopathic mouse
model (Kranias et al., unpublished data) that occursing that this decrease in calcium content must reflect a
regulatory effect, most likely via inhibitory pathways of following the cardiac-specific overexpression of calse-
questrin that displays features of cardiac hypertrophythe SERCA2a activity. To test whether the defect might
PLB Ablation Prevents Progression of Heart Failure
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and dysfunction (Sato et al., 1998). These new studies Since PLB is a direct substrate for phosphorylation by
both cyclic AMP-dependent PKA and Ca21-calmodulin-clearly document that the removal of the inhibitory influ-
ence of PLB not only restores cardiac contractility and dependent kinase, the regulation of cardiac contractil-
ity by cyclic AMP-dependent stimuli may occur via therelaxation, but leads to suprarescue of cardiac contrac-
tility in a manner indistinguishable from those observed phosphorylation of PLB, which in turn prevents the inhib-
itory interaction with SERCA2a. According to this view,in our current study. Thus, in other independent models
of cardiomyopathy, the tonic inhibition of PLB on the the ªsuprarescueº of the cardiomyopathic MLP-defi-
cient mice to supernormal levels in the setting of PLBSR Ca ATPase pump appears to be central for the pro-
gression of in vivo cardiac dysfunction and associated deficiency might simply reflect the removal of the rate-
limiting step in the tonic inhibition of cardiac contractil-decreases in contractility. Taken together, these results
provide the clearest evidence to date that SR calcium ity. Consistent with this notion, recent studies employing
transgenic mice that overexpress an inhibitory peptidecycling is critical to the progression of heart failure and
point to the critical regulatory role of PLB inhibition of for the b-adrenergic receptor kinase (Koch et al. 1995)
have documented that relief of b-adrenergic desensiti-SERCA2a activity in the onset of heart failure in the
setting of dilated cardiomyopathy. zation in the MLP-deficient mice can also lead to signifi-
cant rescue of the dilated cardiomyopathic phenotypeRecently, a number of parallel and converging signal-
ing pathways have been discovered that lead to cardio- (Rockman et al., 1998). Since PLB is an SR protein that
interacts with at least three regulatory components (themyopathy and heart failure (Chien, 1999). There are a
number of distinct genetic and environmental stimuli cyclic AMP-dependent protein kinases, Ca21-calmodulin-
dependent protein kinases, and protein phosphatases),that can lead to various forms of heart failure, and, as
a result, there are likely to be a number of positive and it became critical to determine whether this dominant
effect of PLB ablation on improving cardiac contractilenegative modifiers of the complex heart failure pheno-
type. In fact, studies in MLP-deficient mice have docu- performance reflects the chronic interaction of PLB with
the SERCA2a or whether this rescue effect is related tomented independent genetic background effects that
can promote and suppress the phenotype, leading to the interaction of PLB with other known or novel cardiac
proteins. To directly address this point, we created pointwide alterations in the onset of the phenotype (Arber et
al., 1997). The possibility exists that distinct complemen- mutations in PLB that can interrupt the normal inhibitory
interaction between PLB and SERCA2a. Our mutagene-tation groups will arise that may uncover new pathways
which will modify the course of the disease. In addition, sis strategy was based upon previous studies by Mac-
Lennan and coworkers, which carefully identified thean analogous genetic complementation strategy should
also prove useful in determining whether PLB inhibition precise residues in PLB that are required for maintaining
its interaction with SERCA proteins (Toyofuku et al.,is a critical modifier of other forms of dilated cardio-
myopathy and heart failure. In this regard, a cardiac- 1994; Kimura et al., 1997, 1998). Utilizing recombinant
adenoviruses that force the expression of wild-type, andrestricted knockout of a gp130-dependent myocyte
survival pathway has already been shown to be an im- mutant forms of PLB, we document that the point muta-
portant genetic modifier of acquired forms of heart fail- tions that selectively interrupt PLB±SERCA2a interac-
ure following exposure to the biomechanical stress of tions can dominantly activate cardiac contractility in
pressure overload (Hirota et al., 1999). It will also become cardiac ventricular muscle cells in the absence of cate-
of interest to determine whether PLB ablation would be cholamines. Taken together, these results demonstrate
capable of rescuing heart failure that arises as a result that the progressive defects in EC coupling and heart
of extrinsic signals. failure are most likely related to the increase in the inhibi-
tory effect of PLB on SERCA2a interaction.
A working model can be proposed that outlines thePhospholamban±Sarcoplasmic Reticulum ATPase
Interaction Is a Nodal Point in the Control most likely mechanism responsible for the rescue effect
observed in the DKO mice. Since both PLB and MLPof Cardiac Contractility and Progression
of Dilated Cardiomyopathy are muscle-specific proteins, there must be a muscle
cell-autonomous pathway that is required for the pro-Studies of the double MLP-PLB knockout mice docu-
ment the surprising finding that induction of PLB defi- gression and the rescue of the phenotype, as opposed
to extrinsic stress signals that promote or suppressciency in the setting of a cardiomyopathic mutation can
result in maximal stimulation of cardiac contractile per- myocyte survival pathways, as noted earlier (Hirota et al.,
1999). The proposed model also takes into account ourformance. In fact, the contractility of the DKO hearts at
baseline levels, in the absence of catecholamines, was recent finding that PLB and MLP do not directly interact
at the protein level, thereby eliminating direct interactioncomparable to the contractility of wild-type hearts fol-
lowing maximal b-adrenergic stimulation. This result sug- between PLB and MLP as the basis for the rescue of
cardiac contractile function (unpublished observations).gests that following removal of the tonic inhibition of
SR calcium pump function by PLB, there is essentially Thus, there is a physiological as opposed to a biochemi-
cal (MLP protein±PLB protein interaction) pathway thata ªsuprarescueº in terms of cardiac contractile function
of the cardiomyopathic hearts. This result is surprising, links the PLB regulatory pathways with the onset of
dilated cardiomyopathy. In normal hearts, SR-calciumsince there is a severe refractoriness to b-adrenergic
stimulation in the setting of dilated cardiomyopathy in stores are maintained through the activity of SERCA2a,
which leads to an uptake of calcium into the SR andthis experimental model system that mimics the human
disease in which the b-adrenergic receptor±cAMP sys- consequent maintenance of normal cardiac relaxation
and a reduction in wall stress. Subsequently, SR releasetem is severely downregulated by enhanced sympa-
thetic tone (Bristow et al., 1982; Feldman et al., 1988). of calcium, via the calcium release channel, results in
Cell
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age were stained by the conventional osmium-uranium-lead methoda normal quantal calcium release and the consequent
(Martone et al., 1999). Echocardiography (Tanaka et al., 1996) andactivation of the cardiac myofilaments leading to myo-
hemodynamic evaluation in intact mice (Arber et al., 1997; Palako-cardial contraction. Accordingly, enhanced Ca21 con-
deti et al., 1997) were performed as described previously. Avertin
tent in the SR leads to an enhanced Ca21 release with (2.5%, 20 ml/kg body weight), and xylazine (0.005 mg/g) and keta-
a corresponding increase in cardiac contractility. The mine (0.1 mg/g) mixture were used as anesthesia at echocardiog-
raphy and at cardiac catheterization, respectively. Quantitative RNAactivity of SERCA2a is regulated by the inhibitory effects
dot blot analysis (n 5 4) (Jones et al., 1996) and quantitative Westernof the direct interaction of PLB with SERCA2a, which
blot analysis (n 5 6) (Chu et al., 1996) were performed as previouslycan be relieved by the cyclic AMP-dependent phosphor-
described.ylation of PLB following the delivery of b-adrenergic
stimuli. In the setting of heart failure, there is a relative
Calcium Transient Analysis and SR Calcium Content
decrease in SERCA2a function due to an inhibitory effect Myocytes were isolated from the right ventricular free wall of mice
of PLB that arises due to blunted b-adrenergic respon- as previously described (Ward and Giles, 1997) and were illuminated
siveness. As a result, there is less phosphorylation of with excitation wavelength of 480 nm after incubation with Ca21
sensitive dye fluo-3-AM (1 mg/ml). Changes in fluorescence werePLB and a constitutive inhibition of SERCA2a, via
monitored at 510 nm using a microfluorimeter (FM-1000; Solamerechronic interaction with PLB, leading to a relative de-
Technologies) and recorded digitally for later analysis using custom-crease in SR calcium content versus normal levels. This
ized software Cellsoft (D. Bergman; University of Calgary). Fluores-
decrease in calcium stores is translated into a decrease cence values were calibrated using the equation [Ca21 ]i 5 KD((F 2
in the quantal release of calcium through the calcium Fmin)/(Fmax 2 F)) using an assumed KD of 864 nM (Merritt et al.,
release channel and a consequent decrease in single- 1990). SR calcium content was assessed using a standard caffeine
pulse protocol. SR calcium content was defined as the integratedcell calcium transients and in vivo cardiac contractility.
area of this caffeine-induced calcium transient.In DKO hearts, the inhibitory effect of PLB is removed,
thereby relieving the system from the downstream inhib-
Construction of Mutant Phospholamban Adenovirusitory effects of PLB on the SR calcium pump, resulting
and Gene Transfer
in maintenance of SR calcium uptake and reduction of The sense mutation (Val49Ala) was introduced using PCR-based
wall stress toward normal levels. At the same time, this mutagenesis system provided by Stratagene. Recombinant adeno-
increase in SR calcium content results in maintenance virus expressing wild type and mutant of human PLB were generated
by homologous recombination between plasmid pJM17 and a shut-of normal calcium quantal release, thereby leading to
tle plasmid with RSV promoter and SV40 polyA sequences (Wangmaintenance of normal contractility and relaxation. It is
et al., 1998). The efficient in vivo cardiac gene transfer was per-currently unclear whether the predominantly physiologi-
formed by injecting adenovirus vectors into 1-day-old neonatal
cal pathway that is linked with the prevention of chamber mouse heart (Christensen et al., 1999). Myocytes were isolated 4
dilation and the other phenotypic features of dilated weeks after injection, and cell shortening was measured as de-
cardiomyopathy arises as a result of a physiological scribed previously (Minamisawa et al., 1999). Myocytes harboring
transgenes were identified by cotransfection of adenoviral vectorseffect of enhanced cardiac contractility, relaxation, or
expressing GFP as a marker.both. However, since stress pathways lie at the center
of all of the known genetic pathways for dilated cardio-
Acknowledgmentsmyopathy (Chien, 1999), the reduction of wall stress in
DKO mice most likely accounts for the observed pheno- We are grateful to Dr. Sylvia M. Evans, Dr. Kirk U. Knowlton, Dr.
typic rescue of chamber dilation and wall thinning. It Michell Piovant, Dr. Ju Chen, and Dr. Gerald W. Dorn II for fruitful
will also be of interest to examine potential intersection discussions. Nancy Dalton, Andrea Thor, Julie Anderson, Dr. Motoko
Omura-Minamisawa, Wendy Bardwell, and Diane McGirk providedof Ca21 cycling physiological defects in heart failure with
expert technical assistance. This work was supported by Nationalknown Ca21 biochemical signaling pathways for various
Institutes of Health grants to K. R. C., J. R., Jr., and E. G. K. (HL26057,features of hypertrophy (Gruver et al., 1993; McDonough
HL52318, P40RR12358, SCOR 5P50, HL53773), and to the National
et al., 1997; Ramirez et al., 1997; Molkentin et al., 1998). Center for Microscopy and Imaging Research at San Diego (NIH
Genetic complementation strategies which are directed RR04050).
at other components of cardiac calcium cycling should
be informative to resolve whether enhanced contractility Received June 18, 1999; revised September 22, 1999.
or relaxation is the primary physiological effect of PLB
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